concise.news
OriginalSourceMarketWatchUnited StatesOwner: Dow Jones & CompanyLeanCenterCredibilityPublished17:52 UTCRatings: AllSides, MBFCSourceMarketWatchUnited StatesOwner: Dow Jones & CompanyLeanCenterCredibilityPublished17:52 UTCRatings: AllSides, MBFC

“Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss”

“Several medical studies have found that people taking GLP-1 medications have an elevated risk for nonarteritic anterior ischemic optic neuropathy, or NAION.”

GLP-1 drugs may carry a risk of vision loss, including NAION.

Read at MarketWatch

Other reports

How it got here

  1. MarketWatch publishes the article.

  2. concise.news reads it.

  3. Grouped with 8 other reports as story 9.

  4. The Brief ranks it 9th.

    9
    Health

    FDA requires GLP-1 drugs to warn about potential vision loss risk.

    NAION is an eye stroke that can cause sudden, permanent vision loss and has no proven treatment.

    SourcesSTAT15:56 UTCMarketWatch17:52 UTCQuartz18:50 UTCThe Independent20:20 UTCAP News20:27 UTCThe Washington Post20:50 UTCNew York Post20:51 UTCGizmodo21:46 UTCCBS News00:09 UTC
    9

    FDA requires GLP-1 drugs to warn about potential vision loss risk.

    NAION is an eye stroke that can cause sudden, permanent vision loss and has no proven treatment.
    SourcesSTAT15:56 UTCMarketWatch17:52 UTCQuartz18:50 UTCThe Independent20:20 UTCAP News20:27 UTCThe Washington Post20:50 UTCNew York Post20:51 UTCGizmodo21:46 UTCCBS News00:09 UTC